Switch theme
Sign up to access all valuation multiples
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
2019
173
LTM Revenue $27.1M
LTM EBITDA -$161M
-$278M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ITeos Therapeutics has a last 12-month revenue of $27.1M and a last 12-month EBITDA of -$161M.
In the most recent fiscal year, ITeos Therapeutics achieved revenue of $35.0M and an EBITDA of -$153M.
ITeos Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ITeos Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $12.6M | $35.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$144M | -$153M | XXX | XXX | XXX |
| EBITDA Margin | -1143% | -437% | XXX | XXX | XXX |
| Net Profit | $96.7M | -$113M | XXX | XXX | XXX |
| Net Margin | 767% | -322% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ITeos Therapeutics's stock price is $6.
ITeos Therapeutics has current market cap of $211M, and EV of -$278M.
See ITeos Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$278M | $211M | XXX | XXX | XXX | XXX | $-3.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ITeos Therapeutics has market cap of $211M and EV of -$278M.
ITeos Therapeutics's trades at -10.3x LTM EV/Revenue multiple, and 1.7x LTM EBITDA.
Analysts estimate ITeos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ITeos Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$278M | XXX | XXX | XXX |
| EV/Revenue | -8.0x | XXX | XXX | XXX |
| EV/EBITDA | 1.8x | XXX | XXX | XXX |
| P/E | -1.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpITeos Therapeutics's NTM/LTM revenue growth is -70%
ITeos Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, ITeos Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ITeos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ITeos Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 178% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -437% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -508% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 140% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 416% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 541% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ITeos Therapeutics acquired XXX companies to date.
Last acquisition by ITeos Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ITeos Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ITeos Therapeutics founded? | ITeos Therapeutics was founded in 2019. |
| Where is ITeos Therapeutics headquartered? | ITeos Therapeutics is headquartered in United States of America. |
| How many employees does ITeos Therapeutics have? | As of today, ITeos Therapeutics has 173 employees. |
| Who is the CEO of ITeos Therapeutics? | ITeos Therapeutics's CEO is Dr. Michel Detheux, PhD. |
| Is ITeos Therapeutics publicy listed? | Yes, ITeos Therapeutics is a public company listed on NAS. |
| What is the stock symbol of ITeos Therapeutics? | ITeos Therapeutics trades under ITOS ticker. |
| When did ITeos Therapeutics go public? | ITeos Therapeutics went public in 2020. |
| Who are competitors of ITeos Therapeutics? | Similar companies to ITeos Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ITeos Therapeutics? | ITeos Therapeutics's current market cap is $211M |
| What is the current revenue of ITeos Therapeutics? | ITeos Therapeutics's last 12-month revenue is $27.1M. |
| What is the current EBITDA of ITeos Therapeutics? | ITeos Therapeutics's last 12-month EBITDA is -$161M. |
| What is the current EV/Revenue multiple of ITeos Therapeutics? | Current revenue multiple of ITeos Therapeutics is -10.3x. |
| What is the current EV/EBITDA multiple of ITeos Therapeutics? | Current EBITDA multiple of ITeos Therapeutics is 1.7x. |
| What is the current revenue growth of ITeos Therapeutics? | ITeos Therapeutics revenue growth between 2023 and 2024 was 178%. |
| Is ITeos Therapeutics profitable? | Yes, ITeos Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
